2020 World Young Scientist Summit Fosters a Global Youth Community for Science and Innovation
20.10.2020 13:38:00 EEST | Business Wire | Press release
The 2020 World Young Scientist Summit (WYSS) was held on October 18-19, 2020, in Wenzhou, Zhejiang Province, bringing together representatives from 125 countries/regions and international organizations. Participants included world-class scientists, Nobel laureates, and 113 academics from China and overseas, around 70% of whom were aged under 45.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201020005621/en/
Young scientists recite the Wenzhou Declaration of the World Young Scientist Summit in multiple languages on October 18, 2020. (Photo: Xinhua/Cuili)
The WYSS is an annual event for leading young global talent, jointly sponsored by the China Association for Science and Technology (CAST) and the People's Government of Zhejiang Province.
The 2020 Summit boasted an extensive program divided into four sections: Moment of Science, Dialogue with the Future, Engagement & Sharing, and Realizing Dreams, and included around 30 sessions and activities, such as the Global Young Scientist Scholar Roundtable and International Forum on Comprehensive Healthcare.
Due to the pandemic, the Summit was held both online and offline to allow participants across the globe to connect and converse with each other. Adopting the theme “Converging the World's Talents, Creating a Better Future,” it served as an international, youth-oriented, science-focused platform to develop a global vision, discuss international issues, share China’s perspectives, and also present Zhejiang to the world.
The worldwide spread of COVID-19 has brought dramatic changes to the global public health system and international order. As future world leaders, young scientists have a responsibility to share knowledge and ideas to build a community with a shared future for humankind and help create better lives for people around the globe. According to Wan Gang, Vice Chairman of the National Committee of the Chinese People's Political Consultative Conference and President of the Chinese Association for Science and Technology, China has officially joined the WHO-led program COVAX, to work with the international community to address global uncertainties caused by the pandemic.
During the Summit, the 16th China Youth Science and Technology Award Ceremony was also held to recognize 100 young scientists selected for their outstanding contributions to the nation's socio-economic development and science, technology, and innovation.
This year, the Summit added a new session, the Global Young Scientist Scholar Roundtable, co-hosted by several international organizations, including the Young Earth Scientists (YES) Network, the Global Young Academy, the World Academy of Sciences, and the UN Human Settlements Programme, where the participants from China and abroad jointly issued the “Wenzhou Declaration of the World Young Scientist Summit”.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005621/en/
Contact information
Wei Wang
info@xinhuaeurope.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 07:00:00 EEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 13:41:00 EEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom